Side effects and drug interactions with gliclazide

Reactions ◽  
1984 ◽  
Vol 96 (1) ◽  
pp. 10-11
Keyword(s):  
Side Effects ◽  
Drug Interactions

Practical prescribing

1987 ◽  
Vol 25 (20) ◽  
pp. 80-80
Author(s):  
Martin J Brodie ◽  
Ian Harrison
Keyword(s):  
Side Effects ◽  
Drug Interactions ◽  
Shelf Life ◽  
Text Book ◽  
The Third ◽  
New Drug ◽  
Making Choices ◽  
Treatment Policies ◽  
Accessible Form

This book is a practical manual for the prescriber rather than a text book. The first chapter usefully explains pharmacological terms which are used later in the book. This is followed by three sections concerned with choosing drugs. The first section gives a list of ‘best buys’ for common complaints, the second looks at treatment policies and the third gives basic pharmacological information to help in making choices. Side-effects and drug interactions are presented in the next two chapters in a readily accessible form. The final chapter, called ‘Cautions,’ has some useful information not readily found elsewhere including data on teratogenesis and shelf-life of formulations. It also suggests which drugs we should stop using, and discusses factors to consider before using a new drug.

scholarly journals Update on therapy for superficial mycoses: review article part I

2013 ◽  
Vol 88 (5) ◽  
pp. 764-774 ◽  
Author(s):  
Maria Fernanda Reis Gavazzoni Dias ◽  
Maria Victoria Pinto Quaresma-Santos ◽  
Fred Bernardes-Filho ◽  
Adriana Gutstein da Fonseca Amorim ◽  
Regina Casz Schechtman ◽  
...  
Keyword(s):  
Side Effects ◽  
Drug Interactions ◽  
Fungal Infections ◽  
Review Article ◽  
Practical Approach ◽  
Superficial Mycoses ◽  
World Markets ◽  
The World ◽  
The Right ◽  
Therapeutic Alternatives

Superficial fungal infections of the hair, skin and nails are a major cause of morbidity in the world. Choosing the right treatment is not always simple because of the possibility of drug interactions and side effects. The first part of the article discusses the main treatments for superficial mycoses - keratophytoses, dermatophytosis, candidiasis, with a practical approach to the most commonly-used topical and systemic drugs , referring also to their dosage and duration of use. Promising new, antifungal therapeutic alternatives are also highlighted, as well as available options on the Brazilian and world markets.

scholarly journals The importance of psychological messages and the “questionbehavior effect” about remdesivir

2021 ◽  
pp. 124-126
Author(s):  
Aloisio Antonio Gomes de Matos ◽  
Séphora Natércia Albuquerque Oliveira ◽  
Modesto Leite Rolim Neto
Keyword(s):  
Mental Health ◽  
Side Effects ◽  
Health Services ◽  
Drug Interactions ◽  
Healthcare Providers ◽  
Self Esteem ◽  
Scientific Basis ◽  
High Expectations ◽  
The World

Background: The FDA has been requiring that information about using remdesivir to treat COVID-19 be made available to healthcare providers and patients, including dosing instructions, potential side effects, and drug interactions. It is important to observe the initial indicators of anxiety, fear, and euphoria for families during emergencies, including information on the possible side effects. This situational context is very important in all the world, because it opens doors for providing the use of updated information about treatment follow-up and for offering improved mental health services. Method: The studies were identified in well-known international journals found in two electronic databases: Scopus and Embase. The data were cross-checked with information from the main international newspapers. Results: The high expectations supported by an immediate discourse culminate in frustration and displeasure, while more consistent empirical results are not generated. These two are predictors of psychic suffering, especially due to the scarcity of information and uncertainties. In parallel, recent studies indicate that spreading information without scientific basis intensifies damage to the routine and health of people, which are already impacted by the pandemic situation. This misrepresented spread may be a factor for unleashing fear and, as a consequence, social despair. Conclusions: Based on the impulsive scenarios stimulated in the context of hydroxychloroquine and on the high spread of fake or distorted news, the psychiatric impacts of COVID-19 pandemic associated with the use of remdesivir may be worsened and reflected directly on the population’s self-esteem.

scholarly journals Modeling Polypharmacy Side Effects with Graph Convolutional Networks

2018 ◽  
Author(s):  
Marinka Zitnik ◽  
Monica Agrawal ◽  
Jure Leskovec
Keyword(s):  
Side Effects ◽  
Drug Interactions ◽  
Protein Interactions ◽  
Side Effect ◽  
Population Data ◽  
Model Parameters ◽  
Mortality And Morbidity ◽  
Convolutional Networks ◽  
Important Challenge ◽  
Complex Relationships

AbstractMotivation: The use of drug combinations, termed polypharmacy, is common to treat patients with complex diseases or co-existing conditions. However, a major consequence of polypharmacy is a much higher risk of adverse side effects for the patient. Polypharmacy side effects emerge because of drug-drug interactions, in which activity of one drug may change, favorably or unfavorably, if taken with another drug. The knowledge of drug interactions is often limited because these complex relationships are rare, and are usually not observed in relatively small clinical testing. Discovering polypharmacy side effects thus remains an important challenge with significant implications for patient mortality and morbidity.Results: Here, we present Decagon, an approach for modeling polypharmacy side effects. The approach constructs a multimodal graph of protein-protein interactions, drug-protein target interactions, and the polypharmacy side effects, which are represented as drug-drug interactions, where each side effect is an edge of a different type. Decagon is developed specifically to handle such multimodal graphs with a large number of edge types. Our approach develops a new graph convolutional neural network for multirelational link prediction in multimodal networks. Unlike approaches limited to predicting simple drug-drug interaction values, Decagon can predict the exact side effect, if any, through which a given drug combination manifests clinically. Decagon accurately predicts polypharmacy side effects, outperforming baselines by up to 69%. We find that it automatically learns representations of side effects indicative of co-occurrence of polypharmacy in patients. Furthermore, Decagon models particularly well polypharmacy side effects that have a strong molecular basis, while on predominantly non-molecular side effects, it achieves good performance because of effective sharing of model parameters across edge types. Decagon opens up opportunities to use large pharmacogenomic and patient population data to flag and prioritize polypharmacy side effects for follow-up analysis via formal pharmacological studies.Availability: Source code and preprocessed datasets are at: http://snap.stanford.edu/decagon.Contact:[email protected]

Food and drug interactions: its side effects

2005 ◽  
Vol 35 (4) ◽  
pp. 243-252 ◽  
Author(s):  
J.A. Ayo ◽  
H. Agu ◽  
I. Madaki
Keyword(s):  
Side Effects ◽  
Drug Interactions

Herbal Drug Interactions

2017 ◽  
pp. 201-231 ◽  
Author(s):  
Mymoona Akhter
Keyword(s):  
Drug Interaction ◽  
Side Effects ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Herbal Medicines ◽  
Herbal Drugs ◽  
Herbal Drug ◽  
Herbal Therapy ◽  
Alternative Medicines ◽  
Regulatory Bodies

Use of complementary and alternative medicines (CAM) for preventive and therapeutic purposes has increased tremendously in the last two decades internationally. The manufacturers of these products are not required to submit proof of safety or efficacy to the Food and Drug Administration. As a result, the adverse effects and drug interactions associated with them are largely unknown. In this chapter, the author presents interactions of herbal medicines with other medicines (herbal or non-herbal). A large number of herbal drugs, including from single drug to a variety of mixtures have been used to treat kidney disorders. Herb-herb or herb drug interaction has been reported intensively during last decade, therefore it becomes important to keep an eye on the use of combination herbal therapy in order to avoid serious results because of interactions with each other. Due to the growing awareness about the interactions and side effects of herbal drugs/supplements over the past few years, regulatory bodies are working on these issues and pharmacopoeias are being developed for reference.

Monoamine Agonists (“Antidepressants”), Including Dopamine Agonists (“Stimulants”)

2018 ◽  
pp. 85-100
Author(s):  
S. Nassir Ghaemi
Keyword(s):  
Clinical Pharmacology ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Drug Interactions ◽  
Psychotropic Drugs ◽  
Withdrawal Syndrome ◽  
Serotonin Reuptake ◽  
Dopamine Agonists ◽  
Serotonin Reuptake Inhibitors ◽  
Norepinephrine Reuptake

The drug class of monoamine agonists includes agents called antidepressants and stimulants. Monoamine agonists are the most widely used class of psychotropic drugs. There are three major monoamines, and thus three main types of monoamine agonists. We consider each in turn: the serotonin reuptake inhibitors (SRIs), norepinephrine reuptake inhibitors (NRIs), and dopaminergic agents. We also discuss the dopamine agonists—bupropion (Wellbutrin) and amphetamines (“stimulants”), as well as other new monoamine agonists. The clinical pharmacology of specific agents within each class, including their efficacy and side effects, is explored. Specific phenomena surveyed include SRI tolerance, sexual dysfunction, drug interactions, serotonin withdrawal syndrome, and suicide and akathisia.

Drug Information

2019 ◽  
pp. 299-698
Author(s):  
John G. Bartlett ◽  
Robert R. Redfield ◽  
Paul A. Pham
Keyword(s):  
Side Effects ◽  
Drug Interactions ◽  
Amphotericin B ◽  
Drug Information ◽  
Antiviral Agents ◽  
Pegylated Interferon

Abstract: This chapter is about pharmacology, side effects, and drug interactions of various drugs, including abacavir (ABC), acyclovir, Amphotericin B, atazanavir (ATV), atorvastatin, atovaquone, azithromycin, azoles, bedaquiline, bictegravir (BIC), bupropion, buspirone, caspofungin, cidofovir, ciprofloxacin, clarithromycin, clindamycin, clotrimazole, cobicistat (COBI), dapsone, darunavir (DRV), daunorubicin citrate liposome, didanosine (ddI), dolutegravir (DTG), doxycycline, efavirenz (EFV), emtricitabine (FTC), elvitegravir (EVG), enfuvirtide (T-20), entecavir, erythropoietin, ethambutol, etravirine (ETR), fentanyl, fluconazole, flucytosine, fluoxetine, fosamprenavir (FPV), ibalizumab-uiyk (Trogarzo), indinavir (IDV), itraconazole, lamivudine (3TC), leucovorin, lopinavir/ritonavir (LPV/r), maraviroc (MVC), methadone, nelfinavir (NFP), nevirapine (NVP), oxandrolone, paromomycin, pegylated interferon, pentamidine, pravastatin, pyrazinamide, pyrimethamine, raltegravir (RAL), ribavirin, rifabutin, rifampin, rilpivirine (RPV), ritonavir (RTV), saquinavir (SQV), stavudine (d4T), sulfadiazine, tenofovir (TDF and TAF), testosterone, thalidomide, tipranavir (TPV), trazodone, trimethoprim, trimethoprim-sulfamethoxazole, voriconazole,zidovudine, and Hep C antiviral agents.

Drugs and prescribing in the older patient

2020 ◽  
pp. 571-578
Author(s):  
Miles Witham ◽  
Jacob George ◽  
Denis O’Mahony
Keyword(s):  
Side Effects ◽  
Life Expectancy ◽  
Drug Metabolism ◽  
Older People ◽  
Drug Interactions ◽  
Central Component ◽  
Pharmacological Agents ◽  
Limited Life Expectancy ◽  
Limited Life ◽  
Great Harm

The use of pharmacological agents is often a central component of medical therapy for older people. Medications can relieve symptoms, improve function, and prevent illness, but they also have the capacity to inflict great harm. Older people are at particular risk of such harms as a result of impaired homeostatic reserve, of altered drug metabolism, the presence of multimorbidity and consequent polypharmacy, which increases both exposure to potentially harmful agents and the chance of drug–drug interactions. The therapeutic priorities for older, frail people may differ when compared to younger, robust patients; limited life expectancy means that attempts to prolong life may become relatively less important than the relief of symptoms and avoidance of side effects and medication burden.

Sign in / Sign up

Export Citation Format

Share Document